Navigation Links
Promising Data ATIR Studies Presented by NIH Investigators
Date:11/28/2007

AMSTERDAM, November 28 /PRNewswire/ -- Kiadis Pharma announced today the presentation of the results obtained so far in the physician initiated study led by Dr. Stephan Mielke* and Dr. John Barrett* of the National Heart, Lung, and Blood Institute (NHLBI) a department of the National Institutes of Health (NIH) on Kiadis' lead product ATIR at the AABB annual meeting & TXPO 2007 in Anaheim, California.

According to the NHLBI investigators the challenge in the field of allogeneic bone marrow transplantations lies with disease control, Graft versus Host Disease (GvHD) control and donor availability. Doctors Barrett and Mielke have focused on controlling GvHD whilst sparing the Graft versus Leukemia (GvL) effect and also on increasing donor availability.

The investigators have published the preclinical data showing promising results with Kiadis Pharma's ATIR in eliminating alloreactive T cells from donor grafts (Mielke et al. Blood, 2007). These results have led to the start of a phase II study with ATIR by the NHLBI. This trial is designed to demonstrate that ATIR treatment may overcome the need of immunosuppressant prophylaxis post transplantation. Prophylaxis is currently standard practice to prevent GvHD, but has a serious drawback, as it increases the chance of infection and also the relapse rate. Thus ATIR does not only intend to prevent GvHD, but could also reduce the rates of infection and relapse. Together, these complications account for approximately 70 % of allogeneic transplant related mortality.

For the complete press release go to http://www.kiadis.com/News

*Note

Dr John Barrett is Chief of the Allotransplant Section at National Heart, Lung, and Blood Institute (NHLBI) of National Institutes of Health (NIH) in Bethesda, MD, USA, where the trial is being performed. Dr Stephan Mielke, who initiated this study as principal investigator at NHLBI, is currently working at the Julius-Maximilians University of Wurzburg, Germany and continues as the lead associate investigator on the protocol.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
5. Argonne researcher studies what makes quantum dots blink
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for the ... Qualification Course for Technicians via a two part webinar on July 30 and August ... of hardware, software, and camera setup/operations, aligns with the in-person member qualification course that ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... former Vice President for Public Policy for the National Organization for Rare Disorders ... advocacy groups to ensure their voices are heard throughout the drug regulatory review ...
(Date:2/9/2016)... NEW YORK , Feb. 9, 2016 ... market analyzes the current and future prospects of the ... of this report include companies engaged in the manufacture ... comprises an executive summary with a market snapshot providing ... the scope of this report. This section also provides ...
(Date:2/9/2016)... , February 9, 2016 Three-Year Initiative ... Children to Take Part in Life-Changing Camp ... initiative designed to positively affect the lives of children born with ... --> SHPG ) is announcing a new initiative designed ... as well as the future of rare disease care. --> ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):